131 related articles for article (PubMed ID: 1987495)
1. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
Basso D; Panozzo MP; Fabris C; Meggiato T; Faggian D; Fogar P; Scalon P; Del Favero G; Plebani M; Burlina A
Oncology; 1991; 48(1):22-5. PubMed ID: 1987495
[TBL] [Abstract][Full Text] [Related]
2. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA 19-9 in patients with pancreatic cancer.
Ferrara C; Basso D; Fabris C; Malesci A; Fogar P; Meggiato T; Panozzo MP; Scalon P; Del Favero G; Plebani M
Tumori; 1991 Feb; 77(1):56-60. PubMed ID: 1673269
[TBL] [Abstract][Full Text] [Related]
4. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
5. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
7. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
[TBL] [Abstract][Full Text] [Related]
8. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer.
Fabris C; Basso D; Piccoli A; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Faggian D; Vianello D; Plebani M
J Med; 1991; 22(3):145-56. PubMed ID: 1770322
[TBL] [Abstract][Full Text] [Related]
9. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
Pålsson B; Masson P; Andrén-Sandberg A
Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635
[TBL] [Abstract][Full Text] [Related]
10. Is CA242 really a new tumour marker for pancreatic adenocarcinoma?
Plebani M; Basso D; Navaglia F; D'Angeli F; Panozzo MP; Del Giudice G; Battistel M; Meggiato T; Del Favero G
Oncology; 1995; 52(1):19-23. PubMed ID: 7800337
[TBL] [Abstract][Full Text] [Related]
11. The monoclonal antibody-defined CAR-3 antigen is a serological marker associated with pancreatic carcinoma.
Prat M; Medico E; Piantino P; Bretti S; Rossini FP; Comoglio PM
Int J Biol Markers; 1988; 3(1):29-35. PubMed ID: 2977786
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.
Pearce S; Thornes H; Carr D; Tanner A
Gut; 1994 May; 35(5):707-8. PubMed ID: 8200572
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Plebani M; Basso D; Del Favero G; Ferrara C; Meggiato T; Fogar P; Mangano F; Ricciardi G; Burlina A
Oncology; 1993; 50(6):436-40. PubMed ID: 8233283
[TBL] [Abstract][Full Text] [Related]
14. [Ca 19-9 in the diagnosis of pancreatic carcinoma].
Meggiato T; Basso D; Pasquali C; Angonese C; Bellinvia S; Del Favero G; Fabris C; Di Mario F; Plebani M; Pedrazzoli S
Minerva Med; 1989 May; 80(5):431-4. PubMed ID: 2747969
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
16. CA 242 is a new tumor marker for pancreatic cancer.
Röthlin MA; Joller H; Largiadèr F
Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
[TBL] [Abstract][Full Text] [Related]
17. CA 494--a new tumor marker for the diagnosis of pancreatic cancer.
Friess H; Büchler M; Auerbach B; Weber A; Malfertheiner P; Hammer K; Madry N; Greiner S; Bosslet K; Beger HG
Int J Cancer; 1993 Mar; 53(5):759-63. PubMed ID: 8449599
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic value of radioimmunological analysis of CA-19-9 in the blood serum in cancer of the pancreas].
Putseva NM; Chebotareva ED; Chernyĭ VA; Tashchiev RK
Klin Khir (1962); 1989; (11):15-7. PubMed ID: 2625847
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
[TBL] [Abstract][Full Text] [Related]
20. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
